Abstract OT2-01-21: Phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER-positive/HER2-negative advanced or metastatic breast cancer that has progressed during or after aromatase inhibitor therapy
JA García-Sáenz
◽
E Carrasco
◽
ML Kneissl
◽
F Zohren
◽
M Martin